Skip to main content
Premium Trial:

Request an Annual Quote

Bayer CropScience to Use Fluidigm Tools in Breeding Programs

NEW YORK (GenomeWeb News) – Bayer CropScience will use Fluidigm's integrated fluidic circuit (IFC) technologies in its molecular breeding program, Fluidigm said today.

The agricultural branch of Bayer will use Fluidigm's IFC tools under a global, multi-year agreement, for field and vegetable crops, South San Francisco-based Fluidigm said.
Fluidigm's technologies for high-throughput SNP genotyping in molecular breeding projects include the BioMark and the EP1 systems, and its microfluidic-based Dynamic Array.

Traditional breeding experiments required growing new crops, selecting traits, cross-breeding, and growing seeds again to maturity to check results, a process that could take years and even decades, said Fluidigm. But molecular breeding enables breeders to "dramatically decrease cost and timelines to select the best seeds for the market place," the firm said.

Even the capacity of molecular breeding has been limited, the company noted, adding that its technologies increase output more than 10-fold and lowers the cost-per-data point compared with using 384-well plates for genotyping.

Financial terms of the agreement were not released.

The Scan

Mosquitos Genetically Modified to Prevent Malaria Spread

A gene drive approach could be used to render mosquitos unable to spread malaria, researchers report in Science Advances.

Gut Microbiomes Allow Bears to Grow to Similar Sizes Despite Differing Diets

Researchers in Scientific Reports find that the makeup of brown bears' gut microbiomes allows them to reach similar sizes even when feasting on different foods.

Finding Safe Harbor in the Human Genome

In Genome Biology, researchers present a new approach to identify genomic safe harbors where transgenes can be expressed without affecting host cell function.

New Data Point to Nuanced Relationship Between Major Depression, Bipolar Disorder

Lund University researchers in JAMA Psychiatry uncover overlapping genetic liabilities for major depression and bipolar disorder.